Search Results - "HAYES, D. F"

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 by Curigliano, G, Burstein, H.J., Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

“…The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies…”
Get full text

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome by Miller, P., Kidwell, K. M., Thomas, D., Sabel, M., Rae, J. M., Hayes, D. F., Hudson, B. I., El-Ashry, D., Lippman, M. E.

“…Purpose Elevated S100A8 expression has been observed in cancers of the bladder, esophagus, colon, ovary, and breast. S100A8 is expressed by breast cancer cells…”
Get full text

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age by Desta, Z, Kreutz, Y, Nguyen, A T, Li, L, Skaar, T, Kamdem, L K, Henry, N L, Hayes, D F, Storniolo, A M, Stearns, V, Hoffmann, E, Tyndale, R F, Flockhart, D A

“…The associations between plasma letrozole concentrations and CYP2A6 and CYP3A5 genetic variants were tested in the Exemestane and Letrozole Pharmacogenomics…”
Get full text

The measurement and therapeutic implications of circulating tumour cells in breast cancer by SMERAGE, J. B, HAYES, D. F

“…Circulating tumours cells (CTCs) represent an important biologic link in the spread of breast cancer from primary to metastatic disease. CTCs are strong…”
Get full text

The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response by Giacomini, K M, Brett, C M, Altman, R B, Benowitz, N L, Dolan, M E, Flockhart, D A, Johnson, J A, Hayes, D F, Klein, T, Krauss, R M, Kroetz, D L, McLeod, H L, Nguyen, A T, Ratain, M J, Relling, M V, Reus, V, Roden, D M, Schaefer, C A, Shuldiner, A R, Skaar, T, Tantisira, K, Tyndale, R F, Wang, L, Weinshilboum, R M, Weiss, S T, Zineh, I

“…The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to…”
Get full text

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 by Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Dubsky, P, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, Xu, B

Get full text

Predictors of recovery of ovarian function during aromatase inhibitor therapy by Henry, N.L., Xia, R., Banerjee, M., Gersch, C., McConnell, D., Giacherio, D., Schott, A.F., Pearlman, M., Stearns, V., Partridge, A.H., Hayes, D.F.

“…Aromatase inhibitors (AIs) may cause a rise in estrogen levels due to ovarian function recovery in women with clinical chemotherapy-induced ovarian failure…”
Get full text

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects by Henry, N L, Chan, H-P, Dantzer, J, Goswami, C P, Li, L, Skaar, T C, Rae, J M, Desta, Z, Khouri, N, Pinsky, R, Oesterreich, S, Zhou, C, Hadjiiski, L, Philips, S, Robarge, J, Nguyen, A T, Storniolo, A M, Flockhart, D A, Hayes, D F, Helvie, M A, Stearns, V

“…Background: Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical…”
Get full text

When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer by YAMAUCHI, Hideko, STEARNS, Vered, HAYES, Daniel F

“…c-erbB-2 (HER-2, c-neu) might play a role as a predictive factor in breast cancer. However, the clinical utility of the marker in this disease is still not…”
Get full text

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study by Henry, N L, Pchejetski, D, A'Hern, R, Nguyen, A T, Charles, P, Waxman, J, Li, L, Storniolo, A M, Hayes, D F, Flockhart, D A, Stearns, V, Stebbing, J

“…Background: The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators…”
Get full text

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients by Rae, J M, Sikora, M J, Henry, N L, Li, L, Kim, S, Oesterreich, S, Skaar, T C, Nguyen, A T, Desta, Z, Storniolo, A M, Flockhart, D A, Hayes, D F, Stearns, V

“…The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of…”
Get full text

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment by Jin, Yan, Desta, Zeruesenay, Stearns, Vered, Ward, Bryan, Ho, Herbert, Lee, Kyung-Hoon, Skaar, Todd, Storniolo, Anna Maria, Li, Lang, Araba, Adjei, Blanchard, Rebecca, Nguyen, Anne, Ullmer, Lynda, Hayden, Jill, Lemler, Suzanne, Weinshilboum, Richard M., Rae, James M., Hayes, Daniel F., Flockhart, David A.

“…Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen…”
Get full text

A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors by Marshall, J., Chen, H., Yang, D., Figueira, M., Bouker, K. B., Ling, Y., Lippman, M., Frankel, S. R., Hayes, D. F.

“…Purpose: Expression of the Bcl-2 protein confers resistance to various apoptotic signals. G3139 [oblimersen sodium (Genasense™)] is a phosphorothioate…”
Get full text

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer by Hayes, D F, Walker, T M, Singh, B, Vitetta, E S, Uhr, J W, Gross, S, Rao, C, Doyle, G V, Terstappen, L W M M

“…Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating…”
Get more information

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology by BAST, Robert C, RAVDIN, Peter, HAYES, Daniel F, BATES, Susan, FRITSCHE, Herbert JR, JESSUP, John M, KEMENY, Nancy, LOCKER, Gershon Y, MENNEL, Robert G, SOMMERFIELD, Mark R

“…To update the 1997 clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast and…”
Get full text

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors by Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J.J., Hayes, D.F.

“…Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to…”
Get full text

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers by Simon, Richard M., Paik, Soonmyung, Hayes, Daniel F.

“…The development of tumor biomarkers ready for clinical use is complex. We propose a refined system for biomarker study design, conduct, analysis, and…”
Get full text

Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen by Ntukidem, NI, Nguyen, AT, Stearns, V, Rehman, M, Schott, A, Skaar, T, Jin, Y, Blanche, P, Li, L, Lemler, S, Hayden, J, Krauss, RM, Desta, Z, Flockhart, DA, Hayes, DF

“…Tamoxifen induces important changes in serum lipid profiles in some women; however, little information is available to predict which women will experience…”
Get full text

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients by Shapiro, C L, Hardenbergh, P H, Gelman, R, Blanks, D, Hauptman, P, Recht, A, Hayes, D F, Harris, J, Henderson, I C

“…To assess the cardiac effects of two different cumulative doses of adjuvant doxorubicin and radiation therapy (RT) in breast cancer patients. Two hundred…”
Get more information

Circulating tumour cells: insights into tumour heterogeneity by Hayes, D. F., Paoletti, C.

“…Tumour heterogeneity is a major barrier to cure breast cancer. It can exist between patients with different intrinsic subtypes of breast cancer or within an…”
Get full text